Clinical Research

Finerenone slows kidney decline in non-diabetic CKD trial; pooled analysis suggests broader benefits across CKD

June 08, 2026 由 AI 报道 AI 生成的图像 事实核查

New data presented at the European Renal Association’s 63rd Congress in Glasgow and published in three major medical journals found that finerenone slowed kidney-function decline in adults with chronic kidney disease (CKD) without diabetes and reduced the risk of a combined kidney-and-cardiovascular outcome. A separate pooled analysis that combined results across finerenone studies also reported fewer kidney and heart-failure events in a broader CKD population.